Markets
Trump
(Anna Moneymaker/Getty Images)

Post-shooting, investors are doubling down on a Trump second term

Market prices in a bigger boost to Trump than it did after stunning debate

Matt Phillips

The attempted assassination of Donald Trump at a rally this weekend has investors betting on stocks that are supposed beneficiaries of his presidency, as well as Republican political success more broadly.

On PredictIt, odds of Trump winning the presidency rose to as high as 68% versus 59% on Friday.

Investors are running back the “post-debate” playbook: the price action on Monday resembles June 28, the session after Joe Biden’s poor debate performance seemingly fortified Trump’s electoral prospects.

A thematic basket of stocks compiled by Goldman Sachs of companies that should benefit from Republican victory in the November election are having their best day of the year, up about 1.8% as of 10:40 am ET. They’re outperforming a basket of stocks that would purportedly stand to gain from Democratic political successes by the most this year.

Some companies poised to ride this political wave are posting large gains. Private prison companies GEO Group, and CoreCivic (formerly Corrections Corporation of America) are surging. So are Fannie Mae and Freddie Mac, which would stand to gain from renewed privatization efforts.

Private education firms such as Grand Canyon Education, and private college operator Laureate Education are also trading to the upside.

Coal companies Peabody Energy and Arch Resources are having strong good days, as some traders seemed to bet on reversal of some climate-related Biden administration initiatives.

On the opposite side of the ledger are shares of firms associated with Democratic policies priorities, including solar firms like Maxeon Solar Technologies, Sunnova Energy and First Solarand health-insurance companies that’ve built large businesses around Obamacare’s insurance plan exchanges including HCA Healthcare and Tenet Healthcare.

One big exception from this pattern: Shares of Trump Media & Technology Group are up over 30% this morning after inexplicably having fallen double digits the day following the presidential debate.

In the bond market, the spread between 2- and 30-year US Treasury yields uninverted this morning for the first time since January, driven by higher 30-year yields.

Higher odds of a Trump win aren’t seen as impacting the trajectory for the Federal Reserve’s policy rate in the near term, but are associated with a higher floor for – and more uncertainty surrounding – growth and inflation over the medium term.

“If the market senses that Trump’s chances to win are higher than they were on Friday — then we would expect the back end of the bond market to sell off in the manner we saw in the immediate aftermath of the debate,” writes Michael Purves, CEO and founder of Tallbacken Capital Advisors.

However, foreign exchange markets continue to defy Wall Street’s top prognostication for a second Trump term in office: US dollar strength.

The Dollar Spot Index is flat this morning, and down slightly against the euro — even as economists at Goldman Sachs spotlight the potential negative macro effects Trump’s economic agenda may have on growth and inflation outcomes in the euro area.

More Markets

See all Markets
markets
J. Edward Moreno

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Read more

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Read more
Tasha Matsumoto
8h
Tech rebound propels stocks to best day since May

The S&P 500, Nasdaq 100, and Russell 2000 all climbed higher as the AI trade was back on.

Chicago Bulls Dennis Rodman (91) and Michael Jordan (23) in action, rebounding vs Charlotte Hornets
Max Knoblauch

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets
Luke Kawa

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Big Tech capital expenditure soared in 2025. It’s going up another 50% in 2026.

Big Tech capital expenditure soared in 2025. It’s going up another 50% in 2026.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets
Matt Phillips

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC